Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a woman who developed toxic epidermal necrolysis, potentially linked to an etonogestrel contraceptive implant, suggesting the need for further research into such adverse reactions.

This study compared the long-term efficacy and safety of biologics targeting TNF alpha and IL-12/23 in moderate to severe psoriasis, finding that IL-12/23 inhibitors were more effective at achieving a PASI 75 response, while both treatments showed a similar risk of serious infection and malignancy.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

This case report describes how a treatment with mycophenolate mofetil and prednisone may be effective in managing autoimmune subepidermal blistering dermatosis in dogs while allowing for steroid reduction.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

New retinoids are effective for various skin conditions and are being developed to have fewer side effects.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

This report describes the enhancement of the French SNIIRAM/SNDS healthcare database through external data linkages, highlighting its potential use in medical research despite complexities in the integration process.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

This article reviews triamcinolone acetonide as an intramuscular long-acting steroid therapy for dermatologic disorders but reports no new clinical results.

This study presents the first documented case of dramatic hair regrowth in a systemic lupus erythematosus patient with refractory alopecia following tofacitinib therapy, suggesting a potential new application for JAK inhibitors in difficult-to-treat cutaneous SLE manifestations.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This letter highlights that septicemia or bacteremic shock can be a complication of enemas in elderly men with prostate infections.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.

This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

In this study, a psoriatic patient developed retinoid-induced granulation tissue after long-term oral etretinate therapy, suggesting prolonged use may lead to delayed wound healing.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

Two elderly men developed scalp inflammation after using a gel for skin lesions, which healed with treatment except for some permanent hair loss.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.